Skip to main content
SpringerLink
Log in

Allogene virusspezifische T‑Zellen als innovative Therapieoption

Behandlung der progressiven multifokalen Leukenzephalopathie mit allogenen virusspezifischen T‑Zellen

Allogeneic virus-specific T cells as innovative therapeutic option

Treatment of progressive multifocal leukoencephalopathy with allogeneic virus-specific T cells

  • Arzneimitteltherapie
  • Published:
DGNeurologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Egli A, Infanti L, Dumoulin A, Buser A, Samaridis J, Stebler C et al (2009) Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J Infect Dis 199(6):837–846

    Article  CAS  Google Scholar 

  2. Knowles WA, Pipkin P, Andrews N, Vyse A, Minor P, Brown DW et al (2003) Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol 71(1):115–123

    Article  Google Scholar 

  3. Johnson EM, Wortman MJ, Dagdanova AV, Lundberg PS, Daniel DC (2013) Polyomavirus JC in the context of immunosuppression: a series of adaptive, DNA replication-driven recombination events in the development of progressive multifocal leukoencephalopathy. Clin Dev Immunol 2013:197807

    Article  Google Scholar 

  4. Chen Y, Trofe J, Gordon J, Du Pasquier RA, Roy-Chaudhury P, Kuroda MJ et al (2006) Interplay of cellular and humoral immune responses against BK virus in kidney transplant recipients with polyomavirus nephropathy. J Virol 80(7):3495–3505

    Article  CAS  Google Scholar 

  5. Hariharan S, Cohen EP, Vasudev B, Orentas R, Viscidi RP, Kakela J et al (2005) BK virus-specific antibodies and BKV DNA in renal transplant recipients with BKV nephritis. Am J Transplant 5(11):2719–2724

    Article  CAS  Google Scholar 

  6. Mani J, Jin N, Schmitt M (2014) Cellular immunotherapy for patients with reactivation of JC and BK polyomaviruses after transplantation. Cytotherapy 16(10):1325–1335

    Article  CAS  Google Scholar 

  7. Marshall LJ, Dunham L, Major EO (2010) Transcription factor Spi‑B binds unique sequences present in the tandem repeat promoter/enhancer of JC virus and supports viral activity. J Gen Virol 91(Pt 12):3042–3052

    Article  CAS  Google Scholar 

  8. Cortese I, Reich DS, Nath A (2021) Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease. Nat Rev Neurol 17(1):37–51

    Article  Google Scholar 

  9. Assetta B, Atwood WJ (2017) The biology of JC polyomavirus. Biol Chem 398(8):839–855

    Article  CAS  Google Scholar 

  10. Committee UKCHCSS, Garvey L, Winston A, Walsh J, Post F, Porter K et al (2011) HIV-associated central nervous system diseases in the recent combination antiretroviral therapy era. Eur J Neurol 18(3):527–534

    Article  Google Scholar 

  11. Alstadhaug KB, Myhr KM, Rinaldo CH (2017) Progressive multifocal leukoencephalopathy. Tidsskr Nor Laegeforen 137:23–24

    Google Scholar 

  12. Tan CS, Koralnik IJ (2010) Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol 9(4):425–437

    Article  CAS  Google Scholar 

  13. Sano Y, Nakano Y, Omoto M, Takao M, Ikeda E, Oga A et al (2015) Rituximab-associated progressive multifocal leukoencephalopathy derived from non-Hodgkin lymphoma: neuropathological findings and results of mefloquine treatment. Intern Med 54(8):965–970

    Article  CAS  Google Scholar 

  14. Pavlovic D, Patera AC, Nyberg F, Gerber M, Liu M, Progressive Multifocal Leukeoncephalopathy C (2015) Progressive multifocal leukoencephalopathy: current treatment options and future perspectives. Ther Adv Neurol Disord 8(6):255–273

    Article  CAS  Google Scholar 

  15. von Geldern G, Pardo CA, Calabresi PA, Newsome SD (2012) PML-IRIS in a patient treated with brentuximab. Neurology 79(20):2075–2077

    Article  Google Scholar 

  16. Carson KR, Newsome SD, Kim EJ, Wagner-Johnston ND, von Geldern G, Moskowitz CH et al (2014) Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project. Cancer 120(16):2464–2471

    Article  CAS  Google Scholar 

  17. Schwab N, Schneider-Hohendorf T, Melzer N, Cutter G, Wiendl H (2017) Natalizumab-associated PML: challenges with incidence, resulting risk, and risk stratification. Neurology 88(12):1197–1205

    Article  CAS  Google Scholar 

  18. Monaco MC, Major EO (2015) Immune system involvement in the pathogenesis of JC virus induced PML: what is learned from studies of patients with underlying diseases and therapies as risk factors. Front Immunol 6:159

    Article  Google Scholar 

  19. Maas RP, Muller-Hansma AH, Esselink RA, Murk JL, Warnke C, Killestein J et al (2016) Drug-associated progressive multifocal leukoencephalopathy: a clinical, radiological, and cerebrospinal fluid analysis of 326 cases. J Neurol 263(10):2004–2021

    Article  CAS  Google Scholar 

  20. Clifford DB, Nath A, Cinque P, Brew BJ, Zivadinov R, Gorelik L et al (2013) A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes. J Neurovirol 19(4):351–358

    Article  CAS  Google Scholar 

  21. De Luca A, Ammassari A, Pezzotti P, Cinque P, Gasnault J, Berenguer J et al (2008) Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysis. AIDS 22(14):1759–1767

    Article  Google Scholar 

  22. Hall CD, Dafni U, Simpson D, Clifford D, Wetherill PE, Cohen B et al (1998) Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS Clinical Trials Group 243 Team. N Engl J Med 338(19):1345–1351

    Article  CAS  Google Scholar 

  23. Jamilloux Y, Kerever S, Ferry T, Broussolle C, Honnorat J, Seve P (2016) Treatment of progressive multifocal leukoencephalopathy with mirtazapine. Clin Drug Investig 36(10):783–789

    Article  CAS  Google Scholar 

  24. Smith CA, Ng CY, Heslop HE, Holladay MS, Richardson S, Turner EV et al (1995) Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease. J Hematother 4(2):73–79

    Article  CAS  Google Scholar 

  25. O’Reilly RJ, Small TN, Papadopoulos E, Lucas K, Lacerda J, Koulova L (1997) Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts. Immunol Rev 157:195–216

    Article  Google Scholar 

  26. Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED et al (1995) Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T‑cell clones from the donor. N Engl J Med 333(16):1038–1044

    Article  CAS  Google Scholar 

  27. Cobbold M, Khan N, Pourgheysari B, Tauro S, McDonald D, Osman H et al (2005) Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med 202(3):379–386

    Article  CAS  Google Scholar 

  28. Kaeuferle T, Krauss R, Blaeschke F, Willier S, Feuchtinger T (2019) Strategies of adoptive T‑cell transfer to treat refractory viral infections post allogeneic stem cell transplantation. J Hematol Oncol 12(1):13

    Article  Google Scholar 

  29. Balduzzi A, Lucchini G, Hirsch HH, Basso S, Cioni M, Rovelli A et al (2011) Polyomavirus JC-targeted T‑cell therapy for progressive multiple leukoencephalopathy in a hematopoietic cell transplantation recipient. Bone Marrow Transplant 46(7):987–992

    Article  CAS  Google Scholar 

  30. Muftuoglu M, Olson A, Marin D, Ahmed S, Mulanovich V, Tummala S et al (2018) Allogeneic BK virus-specific T cells for progressive multifocal leukoencephalopathy. N Engl J Med 379(15):1443–1451

    Article  CAS  Google Scholar 

  31. Krymskaya L, Sharma MC, Martinez J, Haq W, Huang EC, Limaye AP et al (2005) Cross-reactivity of T lymphocytes recognizing a human cytotoxic T‑lymphocyte epitope within BK and JC virus VP1 polypeptides. J Virol 79(17):11170–11178

    Article  CAS  Google Scholar 

  32. Hopfner F, Mohn N, Eiz-Vesper B, Maecker-Kolhoff B, Gottlieb J, Blasczyk R et al (2021) Allogeneic BK virus-specific T‑cell treatment in 2 patients with progressive multifocal Leukoencephalopathy. Neurol Neuroimmunol Neuroinflamm 8(4):e1020. https://doi.org/10.1212/NXI.0000000000001020

    Article  Google Scholar 

  33. Wicklein R, Heidegger S, Verbeek M, Eiz-Vesper B, Maecker-Kolhoff B, Kirschke JS et al (2021) Combined treatment with pembrolizumab and allogenic BK virus-specific T cells in progressive multifocal leukoencephalopathy: a case report. Neurol Neuroimmunol Neuroinflamm 8(5):e1042

    Article  Google Scholar 

  34. Cortese I, Beck ES, Al-Louzi O, Ohayon J, Andrada F, Osuorah I et al (2021) BK virus-specific T cells for immunotherapy of progressive multifocal leukoencephalopathy: an open-label, single-cohort pilot study. Lancet Neurol 20(8):639–652

    Article  CAS  Google Scholar 

  35. Steinhardt MJ, Wiercinska E, Pham M, Grigoleit GU, Mazzoni A, Da-Via M et al (2020) Progressive multifocal leukoencephalopathy in a patient post allo-HCT successfully treated with JC virus specific donor lymphocytes. J Transl Med 18(1):177

    Article  CAS  Google Scholar 

  36. Berzero G, Basso S, Stoppini L, Palermo A, Pichiecchio A, Paoletti M et al (2021) Adoptive transfer of JC virus-specific T lymphocytes for the treatment of progressive multifocal leukoencephalopathy. Ann Neurol 89(4):769–779

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Neurologie, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland

    N. Möhn, L. Grote-Levi, F. Hopfner, G. U. Höglinger &  T. Skripuletz

  2. Institut für Transfusionsmedizin und Transplantat Engineering, Medizinische Hochschule Hannover, Hannover, Deutschland

    B. Eiz-Vesper

  3. Klinik für Pädiatrische Hämatologie und Onkologie, Medizinische Hochschule Hannover, Hannover, Deutschland

    B. Maecker-Kolhoff

  4. Klinik für Neurologie, Uniklinik Köln, Köln, Deutschland

    C. Warnke

  5. Institut für Diagnostische und Interventionelle Neuroradiologie, Medizinische Hochschule Hannover, Hannover, Deutschland

    M. P. Wattjes

Authors
  1. N. Möhn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. Grote-Levi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. Hopfner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B. Eiz-Vesper
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. B. Maecker-Kolhoff
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C. Warnke
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M. P. Wattjes
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. G. U. Höglinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. T. Skripuletz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T. Skripuletz.

Ethics declarations

Interessenkonflikt

N. Möhn, L. Grote-Levi, F. Hopfner, B. Eiz-Vesper, B. Maecker-Kolhoff, C. Warnke, M.P. Wattjes, G.U. Höglinger und T. Skripuletz geben an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Additional information

Redaktion

F. Block, Schwerin

S.G. Meuth, Düsseldorf

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Möhn, N., Grote-Levi, L., Hopfner, F. et al. Allogene virusspezifische T‑Zellen als innovative Therapieoption. DGNeurologie 5, 103–109 (2022). https://doi.org/10.1007/s42451-021-00392-w

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s42451-021-00392-w

Search

Navigation